Montelukast Study of Asthma in children (MOSAIC)
Jump to navigation
Jump to search
Introduction
12 month, multicenter, randomized, double-blind study 994 patients, age 6-14 with mild persistent asthma
Treatment:
- montelukast 5 mg PO QD vs fluticasone 100 ug BID via MDI
Primary endpoint:
- % of asthma rescue-free days
Secondary endpoints:
- % of predicted FEV1
- days with beta-agonist use
- quality of life
Results:
- Primary endpoint same in both groups
- Secondary endpoints favored fluticasone